These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10466916)

  • 1. Hyperlipidemia associated with protease inhibitor therapy.
    Echevarria KL; Hardin TC; Smith JA
    Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
    Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
    AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
    Penzak SR; Chuck SK
    Scand J Infect Dis; 2000; 32(2):111-23. PubMed ID: 10826894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperlipidemia associated with the use of protease inhibitors.
    Smith JH; Martin GJ; Decker CF
    Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
    [No Abstract]   [Full Text] [Related]  

  • 12. Intervention for hyperlipidemia associated with protease inhibitors.
    Melroe NH; Kopaczewski J; Henry K; Huebsch J
    J Assoc Nurses AIDS Care; 1999; 10(4):55-69. PubMed ID: 10394560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid abnormalities associated with protease inhibitors.
    Melroe NH; Kopaczewski J; Henry K; Huebsch J
    J Assoc Nurses AIDS Care; 1999; 10(2):22-30. PubMed ID: 10065407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidemia in HIV-positive patients receiving antiretrovirals.
    Segarra-Newnham M
    Ann Pharmacother; 2002 Apr; 36(4):592-5. PubMed ID: 11918504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia under treatment with proteinase inhibitors.
    Segerer S; Bogner JR; Walli R; Loch O; Goebel FD
    Infection; 1999; 27(2):77-81. PubMed ID: 10219634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid lowering therapy in patients with HIV infection.
    McBride M; Chin MT; Lee SM; Kelly B
    Lancet; 1998 Nov; 352(9142):1782-3. PubMed ID: 9848377
    [No Abstract]   [Full Text] [Related]  

  • 18. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV protease inhibitors stimulate hepatic triglyceride synthesis.
    Lenhard JM; Croom DK; Weiel JE; Winegar DA
    Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2625-9. PubMed ID: 11116063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.
    Calza L; Manfredi R; Colangeli V; Pocaterra D; Rosseti N; Pavoni M; Chiodo F
    AIDS Patient Care STDS; 2009 Sep; 23(9):691-7. PubMed ID: 19739937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.